<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564547</url>
  </required_header>
  <id_info>
    <org_study_id>8591-013</org_study_id>
    <secondary_id>2020-003071-18</secondary_id>
    <secondary_id>MK-8591-013</secondary_id>
    <nct_id>NCT04564547</nct_id>
  </id_info>
  <brief_title>Dose Ranging, Switch Study of Islatravir (ISL) and MK-8507 Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]</brief_title>
  <official_title>A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-Daily</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled, double-blind, dose-ranging study evaluating a switch to&#xD;
      islatravir (ISL) and MK-8507 once-weekly in adult participants with human immunodeficiency&#xD;
      virus type 1 (HIV-1) who have been virologically suppressed for ≥6 months on&#xD;
      bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) once-daily. The primary&#xD;
      objectives are to evaluate the antiretroviral activity, safety, and tolerability of ISL with&#xD;
      different doses of MK-8507 compared to continued BIC/FTC/TAF treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 of the study is double-blind and at least 48 weeks in duration. Part 2 will commence&#xD;
      once the dose is confirmed based on data through Week 48 from all participants in Part 1. In&#xD;
      Parts 2 and 3, participants receive open-label treatment through Week 144.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">June 6, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 24, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>Plasma HIV-1 RNA levels will be determined with real time polymerase chain reaction (PCR) assay with a lower limit of quantification (LLoQ) of 40 copies/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with ≥1 adverse event (AE)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>The percentage of participants with AEs will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants discontinuing study intervention due to AE</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>The percentage of participants discontinuing due to AEs will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;50 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>Plasma HIV-1 RNA levels will be determined with real time PCR assay with a LLoQ of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;40 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>Plasma HIV-1 RNA levels will be determined with real time PCR assay with a LLoQ of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA ≥50 copies/mL</measure>
    <time_frame>Week 24</time_frame>
    <description>Plasma HIV-1 RNA levels will be determined with real time PCR assay with a LLoQ of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;50 copies/mL</measure>
    <time_frame>Week 24</time_frame>
    <description>Plasma HIV-1 RNA levels will be determined with real time PCR assay with a LLoQ of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;40 copies/mL</measure>
    <time_frame>Week 24</time_frame>
    <description>Plasma HIV-1 RNA levels will be determined with real time PCR assay with a LLoQ of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA ≥50 copies/mL</measure>
    <time_frame>Week 96</time_frame>
    <description>Plasma HIV-1 RNA levels will be determined with real time PCR assay with a LLoQ of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;50 copies/mL</measure>
    <time_frame>Week 96</time_frame>
    <description>Plasma HIV-1 RNA levels will be determined with real time PCR assay with a LLoQ of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;40 copies/mL</measure>
    <time_frame>Week 96</time_frame>
    <description>Plasma HIV-1 RNA levels will be determined with real time PCR assay with a LLoQ of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (BL) in cluster of differentiation 4+ (CD4+) T-cell count</measure>
    <time_frame>Day 1 (BL) and Week 24</time_frame>
    <description>CD4+ T-cell counts will be determined at the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from BL in CD4+ T-cell count</measure>
    <time_frame>Day 1 (BL) and Week 48</time_frame>
    <description>CD4+ T-cell counts will be determined at the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from BL in CD4+ T-cell count</measure>
    <time_frame>Day 1 (BL) and Week 96</time_frame>
    <description>CD4+ T-cell counts will be determined at the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA ≥50 copies/mL</measure>
    <time_frame>Week 144</time_frame>
    <description>Plasma HIV-1 RNA levels will be determined with real time PCR assay with a LLoQ of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from BL in CD4+ T-cell count</measure>
    <time_frame>Day 1 (BL) and Week 144</time_frame>
    <description>CD4+ T-cell counts will be determined at the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral drug resistance</measure>
    <time_frame>Up to 144 weeks</time_frame>
    <description>Participants with HIV-1 RNA &gt;200 copies/mL will be assessed for development of viral drug resistance. Genotypic and phenotypic resistance will be determined with the commercially available GenoSure PRIme® and PhenoSense® assays, respectively.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Group 1: ISL 20 mg + MK-8507 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive ISL 20 mg (Parts 1-3) + MK-8507 100 mg once weekly (QW) and placebo to BIC/FTC/TAF once daily (QD) [Part 1].</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: ISL 20 mg + MK-8507 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive ISL 20 mg (Parts 1-3) + MK-8507 200 mg QW and placebo to BIC/FTC/TAF QD (Part 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: ISL 20 mg + MK-8507 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive ISL 20 mg (Parts 1-3) + MK-8507 400 mg QW and placebo to BIC/FTC/TAF QD (Part 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: BIC/FTC/TAF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive placebo to ISL + placebo to MK-8507 QW (Part 1) and BIC/FTC/TAF 50 mg/200 mg/25 mg QD (Parts 1 and 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Islatravir</intervention_name>
    <description>ISL capsule taken by mouth.</description>
    <arm_group_label>Group 1: ISL 20 mg + MK-8507 100 mg</arm_group_label>
    <arm_group_label>Group 2: ISL 20 mg + MK-8507 200 mg</arm_group_label>
    <arm_group_label>Group 3: ISL 20 mg + MK-8507 400 mg</arm_group_label>
    <other_name>MK-8591</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8507</intervention_name>
    <description>MK-8507 tablet taken by mouth.</description>
    <arm_group_label>Group 1: ISL 20 mg + MK-8507 100 mg</arm_group_label>
    <arm_group_label>Group 2: ISL 20 mg + MK-8507 200 mg</arm_group_label>
    <arm_group_label>Group 3: ISL 20 mg + MK-8507 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIC/FTC/TAF</intervention_name>
    <description>BIC/FTC/TAF tablet taken by mouth.</description>
    <arm_group_label>Group 4: BIC/FTC/TAF</arm_group_label>
    <other_name>BIKTARVY®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to ISL</intervention_name>
    <description>Placebo capsule matched to ISL taken by mouth.</description>
    <arm_group_label>Group 4: BIC/FTC/TAF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-8507</intervention_name>
    <description>Placebo tablet matched to MK-8507 taken by mouth.</description>
    <arm_group_label>Group 1: ISL 20 mg + MK-8507 100 mg</arm_group_label>
    <arm_group_label>Group 2: ISL 20 mg + MK-8507 200 mg</arm_group_label>
    <arm_group_label>Group 4: BIC/FTC/TAF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BIC/FTC/TAF</intervention_name>
    <description>Placebo tablet matched to BIC/FTC/TAF taken by mouth.</description>
    <arm_group_label>Group 1: ISL 20 mg + MK-8507 100 mg</arm_group_label>
    <arm_group_label>Group 2: ISL 20 mg + MK-8507 200 mg</arm_group_label>
    <arm_group_label>Group 3: ISL 20 mg + MK-8507 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is HIV-1 positive with plasma HIV-1 RNA &lt;50 copies/mL at screening&#xD;
&#xD;
          -  Has been virologically suppressed on BIC/FTC/TAF for ≥6 months&#xD;
&#xD;
          -  Has a screening CD4+ T-cell count &gt;200 cells/mm^3 (completed by the central&#xD;
             laboratory)&#xD;
&#xD;
          -  Is male or female, at least 18 years of age, at the time of signing the informed&#xD;
             consent&#xD;
&#xD;
          -  female participant is eligible to participate if she is not pregnant or breastfeeding,&#xD;
             and at least one of the following conditions applies:&#xD;
&#xD;
          -  Is not a woman of childbearing potential (WOCBP)&#xD;
&#xD;
          -  Is a WOCBP and using a contraceptive method that is highly effective (with a failure&#xD;
             rate of &lt;1% per year), or be abstinent from heterosexual intercourse as their&#xD;
             preferred and usual lifestyle (abstinent on a long term and persistent basis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has HIV-2 infection&#xD;
&#xD;
          -  Has hypersensitivity or other contraindication to any of the components of the study&#xD;
             interventions as determined by the investigator&#xD;
&#xD;
          -  Has active hepatitis C virus (HCV) coinfection (defined as detectable HCV RNA) or&#xD;
             hepatitis B virus (HBV) coinfection (defined as hepatitis B surface antigen&#xD;
             [HBsAg]-positive or HBV deoxyribonucleic acid [DNA] positive)&#xD;
&#xD;
          -  Has a current (active) diagnosis of acute hepatitis due to any cause&#xD;
&#xD;
          -  Has a history of malignancy ≤5 years prior to signing informed consent except for&#xD;
             adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,&#xD;
             or cutaneous Kaposi's sarcoma&#xD;
&#xD;
          -  Has a history or current evidence of any condition (including active tuberculosis&#xD;
             infection), therapy, laboratory abnormality or other circumstance (including drug or&#xD;
             alcohol use or dependence) that might, in the opinion of the investigator, confound&#xD;
             the results of the study or interfere with the participant's participation for the&#xD;
             full duration of the study&#xD;
&#xD;
          -  Is taking or is anticipated to require systemic immunosuppressive therapy, immune&#xD;
             modulators, or any prohibited therapies&#xD;
&#xD;
          -  Is currently participating in or has participated in a clinical study with an&#xD;
             investigational compound or device from 45 days prior to Day 1 through the study&#xD;
             treatment period&#xD;
&#xD;
          -  Has a documented or known virological resistance to MK-8507 or nucleoside/nucleotide&#xD;
             reverse transcriptase inhibitors (NNRTI)&#xD;
&#xD;
          -  Is female and expecting to conceive or donate eggs at any time during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pueblo Family Physicians ( Site 2702)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Men's Health Foundation ( Site 2710)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research ( Site 2713)</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A. ( Site 2712)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Specialists Of Atlanta PC ( Site 2704)</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chatham County Health Department ( Site 2707)</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City CARE Clinic ( Site 2703)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Hope Foundation, Inc. ( Site 2716)</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Centers for Infectious Disease Associates P.A. ( Site 2709)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCOL Center for Clinical Research ( Site 2715)</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hopital Purpan ( Site 2302)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gui de Chauliac. ( Site 2303)</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 2306)</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hotel Dieu Nantes ( Site 2310)</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional du Orleans ( Site 2304)</name>
      <address>
        <city>Orleans</city>
        <state>Loiret</state>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne ( Site 2305)</name>
      <address>
        <city>Bobigny</city>
        <state>Seine-Saint-Denis</state>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis ( Site 2308)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Antoine ( Site 2307)</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zuerich ( Site 2601)</name>
      <address>
        <city>Zuerich</city>
        <state>Aargau</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel ( Site 2602)</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Universitaetsspital Bern ( Site 2603)</name>
      <address>
        <city>Bern</city>
        <state>Berne</state>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve HUG ( Site 2604)</name>
      <address>
        <city>Geneva</city>
        <state>Geneve</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV (centre hospitalier universitaire vaudois) ( Site 2605)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Islatravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

